Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

Daniel R. Feikin, Cheryl M. Elie, Matthew B. Goetz, Jeffrey L. Lennox, George M. Carlone, Sandra Romero-Steiner, Patricia F. Holder, William A. O'Brien, Cynthia G. Whitney, Jay C. Butler, Robert F. Breiman

Research output: Contribution to journalArticlepeer-review

Abstract

In a double-blinded, randomized trial, human immunodeficiency virus (HIV)-infected adults with ≥200 CD4 cells/μl received placebo (PL), 7-valent conjugate, or 23-valent pneumococcal polysaccharide (PS) vaccine in one of the following two-dose combinations given 8 weeks apart: conjugate-conjugate, conjugate-polysaccharide, placebo-polysaccharide, placebo-placebo. A total of 67 persons completed the study. Neither significant increases in HIV viral load nor severe adverse reactions occurred in any group. After controlling for confounders, when compared with persons receiving placebo-polysaccharide, persons receiving conjugate-conjugate and conjugate-polysaccharide had higher antibody concentrations (serotypes 4, 6B, 9V and serotype 23F, respectively) and opsonophagocytic titers (functional antibody assay, serotypes 9V, 23F and serotypes 4, 6B, 9V, respectively) after the second dose (P < 0.05). The second dose with either conjugate or polysaccharide following the first conjugate dose, however, produced no further increase in immune responses. Published by Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)545-553
Number of pages9
JournalVaccine
Volume20
Issue number3-4
DOIs
StatePublished - Nov 12 2001
Externally publishedYes

Keywords

  • Conjugate vaccines
  • HIV
  • Pneumococcal disease

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults'. Together they form a unique fingerprint.

Cite this